Basal Bolus vs. Sliding Scale for Treatment of Diabetic Patients in Medical Wards

This study is not yet open for participant recruitment.
Verified May 2012 by HaEmek Medical Center, Israel
Sponsor:
Information provided by (Responsible Party):
HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier:
NCT01594060
First received: May 7, 2012
Last updated: NA
Last verified: May 2012
History: No changes posted
  Purpose

A comparison of two treatment approaches for hyperglycemia in diabetic patients hospitalized in the medical department. The first approach is called basal-bolus in which 4 insulin shots are given daily ( 3 short acting before meals and one long acting before bed time). The second approach is called sliding scale in which short acting insulin alone is given before meals and before bed time according to the patient's glucose values. The aim is to keep fasting glucose betwene 140-180 mg/dl.


Condition Intervention Phase
Diabetes Mellitus Type 2
Drug: regular insulin
Drug: Insulin glulisine, Insulin glargine
Phase 4

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Randomized, Comparative Study of Basal-bolus Insulin Versus Conventional Sliding-scale Regular Insulin Therapy in Management of Non-critically Ill Patients Hospitalized in the Medical Ward.

Resource links provided by NLM:


Further study details as provided by HaEmek Medical Center, Israel:

Arms Assigned Interventions
Active Comparator: sliding scale Drug: regular insulin
4 shots of regular insulin: 3 before meals and one at bedtime.
Active Comparator: basal bolus Drug: Insulin glulisine, Insulin glargine
1 shot glargine at bedtime 3 shots glulisine before meals

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients admitted to internal medicine ward with blood glucose (BG) between 140-400 mg/dl.
  • Known history (>6months) of diabetes.
  • Aged 18-80 years old.
  • Previous therapy including either diet alone or any combination of oral hypoglycemiants agents, glucagon-like peptide 1 (GLP-1) analogs and long acting insulin analogs or Neutral Protamine Hagedorn (NPH).

Exclusion Criteria:

  • Pregnancy
  • Patients with ketoacidosis
  • Patients with unknown history of diabetes
  • Patients with type 1 diabetes mellitus
  • Patients with clinically relevant hepatic disease or renal impairment ( serum creatinine≥2.5 mg/dl)
  • Use of corticosteroid therapy
  • Patient with any mental disorder preventing him to cooperate and give informed consent.
  • Patients on multiple daily doses of insulin regimen.
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier: NCT01594060     History of Changes
Other Study ID Numbers: 0042-12-EMC
Study First Received: May 7, 2012
Last Updated: May 7, 2012
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Glargine
Insulin glulisine
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 17, 2014